Autori italiani pubblicano

Occlusion of the infarct-related coronary artery presenting as acute coronary syndrome with and without ST-elevation: impact of inflammation and outcomes in a real-world prospective cohort

In questa sottoanalisi tratta dal registro multicentrico prospettico SPUM-ACS che ha raccolto 4.787 pazienti con sindrome coronarica acuta (sia STEMI che NSTEMI) in quattro centri di terzo livello in Svizzera, abbiamo analizzato l’incidenza e l’impatto prognostico dell’occlusione coronarica acuta totale (definita come flusso TIMI 0 all’angiografia) senza evidenza all’ECG di sopraslivellamento del tratto ST nei pazienti con NSTEMI. Comunemente, circa il 20-30% dei pazienti che si presentano con sindrome coronarica acuta hanno un’occlusione completa della coronaria culprit, ma non presentano tratto ST-T sopraslivellato e quindi non vengono indirizzati tempestivamente in sala di emodinamica per un trattamento precoce…

LEGGI TUTTO »

Electrical storm treatment by percutaneous stellate ganglion block: the STAR study

Background and aims: An electrical storm (ES) is a clinical emergency with a paucity of established treatment options. Despite initial encouraging reports about the safety and effectiveness of percutaneous stellate ganglion block (PSGB), many questions remained unsettled and evidence from a prospective multicentre study was still lacking. For these purposes, the STAR study was designed.

Methods: This is a multicentre observational study enrolling patients suffering from an ES refractory to standard treatment from 1 July 2017 to 30 June 2023. The primary outcome was the reduction of treated arrhythmic events by at least 50% comparing the 12 h following PSGB with the 12 h before the procedure. STAR operators were specifically trained to both the anterior anatomical and the lateral ultrasoundguided approach.

LEGGI TUTTO »

Transcatheter Aortic Valve Replacement Without On-Site Cardiac Surgery: Ready for Prime Time?

A oggi, la TAVI è diventata la terapia standard della stenosi valvolare aortica con conseguente rapido incremento del numero di procedure in tutto il mondo. Le attuali Linee Guida raccomandano l’esecuzione della TAVI in ospedali dotati di cardiochirurgia on-site. L’esponenziale aumento di richieste rischia di superare la capacità di questi centri, determinando un prolungamento delle liste di attesa e della mortalità a essa associata. Il nostro lavoro ha l’intento di offrire un modello organizzativo per poter estendere le procedure di TAVI anche in ospedali non dotati di cardiochirurgia on-site. Per sostenere questa ipotesi abbiamo eseguito una meta-analisi sugli studi a oggi disponibili, su un totale di 21.173 TAVI, e l’assenza di cardiochirurgia in loco non aumenta il rischio di morte a breve termine. Elemento fondamentale, secondo il nostro modello, è l’adeguata esperienza dei centri e l’attenta valutazione multidisciplinare in sede di Heart Team. Una dettagliata pianificazione pre-procedurale per identificare i pazienti a maggior rischio di complicanze è essenziale per garantire…

LEGGI TUTTO »

Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients: The EASTBOURNE Prospective Registry

EASTBOURNE è un registro prospettico, il più grande mai fatto con pallone medicato, e mostra la sicurezza ed efficacia del Magic Touch, il primo pallone a eluizione di sirolimus che è stato commercializzato in Europa. Vorrei sottolineare che lo studio è completamente “investigator driven” con fondi impiegati solo per la creazione della eCRF e dell’analisi statistica, per cui il suo messaggio deriva dalla collaborazione spontanea di numerosi sperimentatori (un’ottantina) provenienti da 48 centri europei e asiatici. Quindi, a differenza di altri studi similari, non si tratta di studio sponsorizzato e questo, a mio avviso, rafforza il suo messaggio. Il dispositivo, impiegato in 2.440 lesioni coronariche, ha mostrato un tasso di TLR a un anno del 5.9% e nessun caso di occlusione precoce o tardiva del vaso. I risultati a 2 anni, presentati nel corso di EuroPCR 2023, sono in corso di pubblicazione…

LEGGI TUTTO »

Association of right atrial strain and long-term outcome in severe secondary tricuspid regurgitation

Objective: Severe secondary tricuspid regurgitation (STR) causes significant right atrial (RA) volume overload, resulting in structural and functional RA-remodelling. This study evaluated whether patients with severe STR and reduced RA function, as assessed by RA-reservoirstrain (RASr), show lower long-term prognosis. Results: A total of 586 patients with severe STR (age 68±13 years; 52% male) were included. Patients presented with mild right ventricular (RV) dilatation (end-diastolic area 13.8±6.5 cm2/m2) and dysfunction (free-wall strain 16.2±7.2%), and with moderate-to-severe RA dilatation (max area 15.0±5.3 cm2/m2); the median value of RASr was 13%. In the overall population, 10-year overall survival was low (40%, 349 deaths), and was significantly lower in patients with lower RASr (defined by the median value): 36% (195 deaths) for RASr ≤13% compared with 45% (154 deaths) for RASr >13% (log-rank p=0.016). With a median follow-up of 6.6 years, RASr was independently associated with all-cause mortality (HR per 5% RASr increase:0.928; 95% CI 0.864 to 0.996; p=0.038), providing additional value over relevant clinical and echocardiographic covariates (including RA size and RV function/size).

LEGGI TUTTO »

Prosthesis-patient mismatch after transcatheter implantation of contemporary balloon-expandable and self-exspandable valves in small aortic annuli

Background: Evidence of clinical impact of PPM after TAVI is conflicting and might vary according to the type of valve implanted.

Aims: To assess the clinical impact of prosthesispatient mismatch (PPM) after transcatheter aortic valve implantation (TAVI) with balloon-expandable (BEV) and self-expandable valves (SEV) in patients with small annuli.

LEGGI TUTTO »

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

I pazienti ad alto rischio di sanguinamento (HBR) rappresentano una proporzione considerevole (fino al 40%) dei soggetti sottoposti a rivascolarizzazione percutanea (PCI). Nonostante le crescenti evidenze abbiano dimostrato un beneficio di una duplice terapia antiaggregante (DAPT) abbreviata, in questi pazienti (N Engl J Med. 2021;385(18):1643-1655; doi:10.1056/NEJMoa2108749), l’impatto del sesso sugli outcome clinici dopo la PCI rimane sconosciuto. In questa analisi pre-specificata del MASTER DAPT, abbiamo analizzato gli outcome clinici nei pazienti maschi e femmine ad alto rischio di sanguinamento sottoposti a PCI e l’efficacia/sicurezza di una DAPT abbreviata versus terapia standard in base al sesso. I principali risultati della nostra analisi…

LEGGI TUTTO »

Efficacy and safety of left atrial appendage closure compared with oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlledtrials and propensity-matched studies.

Backgrounds: Two recent randomized controlled trials (RCTs), the PROTECT-AF and the PREVAIL, showed that in atrial fibrillation (AF) patients, left atrial appendage closure (LAAC) is comparable to oral anticoagulants (OAC) in the prevention of stroke and could also possibly reduce mortality. Nevertheless, this net clinical benefit was not confirmed in the most recent RCT comparing LAAC vs. OAC, the PRAGUE-17 trial.

Aim: Aim of the present study was to evaluate the efficacy and safety of LAAC compared with OAC among available high-quality studies.

Methods: A systematic search of electronic databases (Medline, Scopus, Embase and the Cochrane Library) was performed to identify eligible RCTs and observational studies with propensity score matching (PSM) analysis. PRISMA guidelines were used for abstracting data and assessing data quality and validity. Outcomes of interest were the occurrence of cardiovascular death (CVD), all-cause death, all-type stroke, and major bleedings.

Results: A total of 3 RCTs and 7 PMS studies involving 25,700 patients were identified. 12,961 patients received LAAC while 12,739 received OAC therapy. After a median follow-up of 2.6 years (IQR 2–4.4), patients who received LAAC had lower risk of CVD (RR = 0.62; 95% CI, 0.51–0.74, I2 = 0%), all-cause death (RR = 0.67; 95% CI, 0.57–0.78, I2 68%) and major bleedings (RR = 0.68; 95% CI, 0.48–0.95 I2 = 87%) compared with patients on OAC. No difference was found between the two groups regarding strokes incidence (RR = 0.94; 95% CI, 0.77–1.15, I2 = 0%).

LEGGI TUTTO »

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Aims: Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk.

LEGGI TUTTO »
Cerca un articolo
Gli articoli più letti
Rubriche
Leggi i tuoi articoli salvati
La tua lista è vuota